PRNewsWire
29 Sept 2026, 01:10 UTC · 2h ago
SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
Verdict
Headline leans bearish. We score SPRY −1.00 across two claims.
Score confirms the headline.
- Headline says
Leans bearish
From its wording — no explicit rating
- Expected · SPRY
−1.00strongly bearish





